AbbVie (ABBV): Rep. Marjorie Taylor Greene (GA14) disclosed a purchase $1K–$15K
Rep. Marjorie Taylor Greene (GA14) disclosed a purchase of AbbVie in the $1K–$15K range.
- $1,001–$15,000
- Reported range · official band, not an exact amount
- 11 days
- Disclosure lag
- Traded
- Aug 4, 2025
- Disclosed
- Aug 15, 2025
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Sep 26, 2024CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
- May 15, 2025CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
- May 22, 2025CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
- Jun 10, 2025FDAFDA drug approval: Mavyret
- Jun 10, 2025FDAFDA drug approval: Mavyret
- Jun 17, 2025CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
- Jul 11, 2025CongressDisclosed sale of ABBV — reported range $1,001 - $15,000
- Jul 22, 2025Congress · 1 personMembers of Congress: 1 purchase, 1 sale
- Aug 4, 2025 · this disclosureCongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
What came next
- Aug 5, 2025Insider · 1 personInsiders: 2 sales (~$2.6M)
- Aug 11, 2025CongressDisclosed partial sale of ABBV — reported range $1,001 - $15,000
- Aug 12, 2025InsiderOfficer sold ~$8.41M of ABBV shares in the open market
- Aug 14, 2025CongressDisclosed partial sale of ABBV — reported range $1,001 - $15,000
- Aug 22, 2025CongressDisclosed partial sale of ABBV — reported range $1,001 - $15,000
- Sep 3, 2025FDAFDA drug approval: Skyrizi
- Sep 3, 2025FDAFDA drug approval: Skyrizi
- Oct 3, 2025Company filing · Form 8-K · ResultsReported its results
- Oct 10, 2025FDAFDA drug approval: Rinvoq
- Oct 30, 2025Federal contract · $21K obligatedDepartment of Defense awarded AbbVie: $21K obligated to date
- Oct 30, 2025Congress · 1 personMembers of Congress: 1 purchase, 1 sale
- Oct 31, 2025Company filing · Form 8-K · ResultsReported its results
- Oct 31, 2025CongressDisclosed sale of ABBV — reported range $1,001 - $15,000
- Nov 4, 2025FDAFDA drug approval: Linzess
- Nov 10, 2025Layoff notice · 5996 Gleason Drive Dublin CA 94568Layoff notice filed in CA: 48 employees
- Nov 10, 2025Layoff notice · 7041 Las Positas Road Livermore CA 94551Layoff notice filed in CA: 9 employees
- Nov 10, 2025Layoff notice · 4410 Rosewood Drive Pleasonton CA 94588Layoff notice filed in CA: 2 employees
How to read House Clerk periodic transaction report
The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.
Full guide: What is the STOCK Act?
What else is on file for AbbVie
For AbbVie, OQRO holds 3 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 3 fund holdings reports (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ABBV page.
Other recent filings by Rep. Marjorie Taylor Greene (GA14)
- House Clerk periodic transaction report at Automatic Data Processing (ADP)Nov 13, 2025
- House Clerk periodic transaction report at Paychex (PAYX)Nov 13, 2025
- House Clerk periodic transaction report at Procter & Gamble (PG)Nov 7, 2025
- House Clerk periodic transaction report at Home Depot (HD)Oct 28, 2025
- House Clerk periodic transaction report at Kinder Morgan (KMI)Oct 28, 2025
The full history of Rep. Marjorie Taylor Greene (GA14) is on the profile page.
How this filing works
Explore the data
Common questions
Which member of Congress traded AbbVie (ABBV) stock, and how much?
Rep. Marjorie Taylor Greene (GA14) disclosed a purchase of AbbVie in the $1K–$15K range. Reported range, not an exact amount.
When did it happen, and when was it made public?
Traded: Aug 4, 2025. Disclosed: Aug 15, 2025. That is 11 days between the two dates.
Why is the amount a range and not an exact figure?
Members of Congress report each trade in a bracket set by law ($1,001 to $15,000, $15,001 to $50,000, and so on), never an exact amount. OQRO keeps the bracket as filed and does not estimate a figure inside it.
Where does this information come from?
From the House Clerk periodic transaction report, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about AbbVie recently?
For AbbVie, OQRO holds 3 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 3 fund holdings reports (13F) dated in the last 90 days. They are listed on the ABBV page.
Does this mean ABBV stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at AbbVie
- SEC Form 144Nov 16, 2026
- SEC Form 13F-HRNov 16, 2026
- SEC Form 4Nov 12, 2026
- SEC Form 144Nov 9, 2026
- House Clerk periodic transaction reportSep 18, 2026
- SEC Form 13F-HRAug 26, 2026
Everything OQRO holds on this company is on its ABBV page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
